Are Long-term NSAIDs safe in AS? Ab#0528 #ACR23 @RheumNow 19,775 AS pts vs 59,325 controls. Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)

2 yrs extension of DRESS-PS study 100+ pts w/ PsA and AxSPA -70% LDA state in both Ctrl & Intervention gps -strong recovery after relapse No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp @RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3

Upadacitinib on wearable device-measure activity SELECT-AXIS 2 Abs#0530 #ACR23 @RheumNow UPA had numerically higher mean daily step counts than PBO 11% improvement v PBO at wk 14 (diff of 345 steps/day) Sedentary pts: 22% improvement in daily step count from b/l on UPA (4% PBO) https://t.co/Gq91TmvfZC

What are effects of TNFi on Lipids in AxSpA? Ab#0531 #ACR23 @RheumNow 320 pts w AS - retrosp cohort, first-line TNFi, not on lipid Rx Chol and TG increase in 1st 3 mos of treatment. LDL & HDL: no signif change Inflam markers/Lipids correlated - suspect due to anti-inflamm effect https://t.co/qT5qUEOEvO

Abs#0501 @RheumNow #ACR23 Uveitis in SpA, from Greece AxSpA: 11.7% Uveitis. RF: HLA-B27 (OR 4.15), periperhal arthritis (OR 3.05) PsA: 2.7% Uveitis. Ass w/ SpA FHx, Axial dis at dx, disease duration Permanent vision loss in 16% AxSpA, 30% PsA pts, all with recurrent uveitis

EISER study: Undiagnosed IBD in SpA Abs#0495 #ACR23 @RheumNow 559 pts, 47% PsA/53% SpA (80% r-AxSpA) Higher mean fecal calprotectin in r-AxSpA (395 vs 305 nrAxSpA/PsA) 14.6% IBD symptoms, 23 patients (4.4% were dx w IBD) Fecal calprotectin & history can uncover IBD #ACRBest

Always great to see UCSD represent at #ACR23! Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events 30% of events occurred postpartum @RheumNow Abs#0722 https://t.co/CqZedfOlBC

Treatment intensification was associated with a higher ASDAS cut-off (2.7) value than the recommended one (≥2.1), the recommended cut-off could be too stringent or consider other factors than disease activity, Webers, El-Din Abst#0517 #ACR23 @RheumNow https://t.co/ZtBXhufxU1 https://t.co/MzvZQoFbvw

Analysis from the DESIR cohort reveal that pregnancy does not aggravate imaging changes in axSpA. Stat significant changes seen on Xray of LSIJ b4 & after delivery (p=0.037) but not worsening. Do these findings also translate to⬇️pain/improved QOL? #ACR23 ABST0513 @RheumNow https://t.co/s6xD2CaPwn

In a subgrp analysis of the SURPASS study by Dr @XBaraliakos et al, there was low spinal prog over 2 yrs in SEC & SDZ-ADL treated pts regardless of +/- Synd/⬆️CRP Synd+ > CRP+ as predictor of radiog prog Again, early dx = early tx #ACR23 ABST0522 @RheumNow https://t.co/fGF4szPJbp

Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc. AE trended higher in normal CRP pts taking Tofa compared to placebo @RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa

Long term safety data for bimekizumab (IL17i) in Psa & axSpA Overall as expected; increased infections (esp fungal/candida) & hepatic events No new signals... uveitis flares is interesting Need H2H of IL17's! IXE vs SEC vs BIM @RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA

Does pregnancy affect axSpA imaging? Large study of 381 pts, in the DESIR cohort, f/up of 5 years. Pregnancy did not aggravate imaging of axSpA women compared to prior to pregnancy. @RheumNow #ACR23 Abs#0513 https://t.co/eeGuxGGB5E

Difficult to treat D2T-axSpA (failure > 3 biologics), affects one in five patients exposed to b/tsDMARDs in this national registry. D2T is more common in women, presence of peripheral involvement, psoriasis, depression, Fakih O Abst#0514 #ACR23 @RheumNow https://t.co/OoymZzzQST https://t.co/EpTqS1C61A

Love teaching about the PsA-AxSpa-IBD venn diagram of disease manifestations Interesting idea, using fecal calprotectin to trigger colonoscopy in pts w/PsA/axSpA ~40% w/pathologic finding, 4.4% dx w/IBD Jives w/my clinical experience @RheumNow #ACR23 Abstr0495 #ACRBest https://t.co/rIQpJnup9v